A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Phase II Study of PEND Chemotherapy in Patients with Refractory/Relapsed Hodgkin Lymphoma
Leukemia and Lymphoma
High-dose chemotherapy with autologous marrow or stem cell rescue (HDC/ASCT) is an effective strategy in patients with relapsed Hodgkin lymphoma. Various chemotherapy regimens have been used for cytoreduction prior to HDC/ASCT. In this study, our objective was to determine the response rate to PEND in a group of patients with relapsed Hodgkin lymphoma. Nineteen patients with relapsed or primary refractory Hodgkin lymphoma underwent treatment with the PEND regimen and received a median of 2doi:10.1080/1042819042000223831 pmid:15370253 fatcat:l7sdrko7izd6vlmvdw4mncftpm